Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:CRVO NASDAQ:OKYO NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.73-4.9%$1.10$0.61▼$5.20$26.61M0.1621.12 million shs1.48 million shsCRVOCervoMed$10.21-4.5%$8.43$1.80▼$20.63$98.91M-0.72113,804 shs171,973 shsOKYOOKYO Pharma$2.25-0.9%$2.70$0.90▼$3.35$85.38M-0.1125,565 shs33,115 shsVXRTVaxart$0.37-3.1%$0.39$0.26▼$1.07$85.37M1.332.87 million shs575,332 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-4.95%+15.33%+66.35%+104.47%-65.30%CRVOCervoMed-4.49%+9.55%+1.59%+33.99%-39.73%OKYOOKYO Pharma-0.88%-1.32%-29.02%+18.42%+104.55%VXRTVaxart-3.14%+3.58%+1.61%-7.99%-56.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.73-4.9%$1.10$0.61▼$5.20$26.61M0.1621.12 million shs1.48 million shsCRVOCervoMed$10.21-4.5%$8.43$1.80▼$20.63$98.91M-0.72113,804 shs171,973 shsOKYOOKYO Pharma$2.25-0.9%$2.70$0.90▼$3.35$85.38M-0.1125,565 shs33,115 shsVXRTVaxart$0.37-3.1%$0.39$0.26▼$1.07$85.37M1.332.87 million shs575,332 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-4.95%+15.33%+66.35%+104.47%-65.30%CRVOCervoMed-4.49%+9.55%+1.59%+33.99%-39.73%OKYOOKYO Pharma-0.88%-1.32%-29.02%+18.42%+104.55%VXRTVaxart-3.14%+3.58%+1.61%-7.99%-56.44%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/ACRVOCervoMed$9.74M9.70N/AN/A$4.50 per share2.27OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/AVXRTVaxart$47.40M1.80N/AN/A$0.26 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-173.31%-102.57%11/13/2025 (Estimated)CRVOCervoMed-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%11/11/2025 (Estimated)OKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/AN/AVXRTVaxart-$66.95M-$0.25N/AN/AN/A-122.63%-91.89%-38.40%11/12/2025 (Estimated)Latest ALLR, VXRT, CRVO, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025ALLRAllarity Therapeutics-$0.21-$0.15+$0.06-$0.15N/AN/A8/8/2025Q2 2025CRVOCervoMed-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.312.31CRVOCervoMedN/A8.208.20OKYOOKYO PharmaN/A0.400.40VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%CRVOCervoMed25.15%OKYOOKYO Pharma2.97%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%CRVOCervoMed35.40%OKYOOKYO Pharma40.46%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1014.62 million14.61 millionNot OptionableCRVOCervoMed49.25 million5.98 millionNot OptionableOKYOOKYO Pharma737.61 million22.39 millionNot OptionableVXRTVaxart120228.92 million222.37 millionOptionableALLR, VXRT, CRVO, and OKYO HeadlinesRecent News About These CompaniesVaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025September 3 at 12:28 PM | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of DirectorsSeptember 3 at 2:16 AM | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.September 2 at 4:30 PM | globenewswire.comConcerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board AccountabilitySeptember 2 at 9:00 AM | globenewswire.comVaxart Granted Extension by Nasdaq to Regain ComplianceAugust 29, 2025 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Here's WhyAugust 29, 2025 | marketbeat.comVaxart Discusses Reverse Stock Split ProposalAugust 21, 2025 | tipranks.comConcerned Vaxart Stockholders Unite to Oppose Vaxart’s Latest Reverse Stock Split and Defend Stockholder RightsAugust 21, 2025 | markets.businessinsider.comConcerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder RightsAugust 21, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Should You Sell?August 16, 2025 | marketbeat.comVaxart, Inc. (VXRT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comVAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comUS orders Vaxart to stop COVID-19 trial amid mRNA wind downAugust 13, 2025 | reuters.comVaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average - Here's WhyAugust 7, 2025 | marketbeat.comVaxart (VXRT) Expected to Announce Earnings on ThursdayAugust 7, 2025 | marketbeat.comVaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split ProposalJuly 31, 2025 | quiverquant.comQVaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on NasdaqJuly 24, 2025 | globenewswire.comOTC Markets Group Welcomes Vaxart, Inc. to OTCQXJuly 8, 2025 | financialpost.comFVaxart Announces Preliminary Results of Annual Meeting of StockholdersJune 13, 2025 | globenewswire.comVaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJune 11, 2025 | globenewswire.comVaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025June 10, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLR, VXRT, CRVO, and OKYO Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.73 -0.09 (-4.95%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.70 -0.03 (-2.02%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.CervoMed NASDAQ:CRVO$10.21 -0.48 (-4.49%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$10.10 -0.11 (-1.08%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.OKYO Pharma NASDAQ:OKYO$2.25 -0.02 (-0.88%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$2.22 -0.02 (-1.11%) As of 09/4/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Vaxart NASDAQ:VXRT$0.37 -0.01 (-3.14%) As of 09/4/2025 03:54 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
